172 related articles for article (PubMed ID: 10429744)
1. Review article: clinical pharmacology of alosetron.
Gunput MD
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
[TBL] [Abstract][Full Text] [Related]
2. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Houghton LA; Foster JM; Whorwell PJ
Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
[TBL] [Abstract][Full Text] [Related]
3. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
4. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and clinical experience with alosetron.
Camilleri M
Expert Opin Investig Drugs; 2000 Jan; 9(1):147-59. PubMed ID: 11060667
[TBL] [Abstract][Full Text] [Related]
6. Alosetron.
Balfour JA; Goa KL; Perry CM
Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
[TBL] [Abstract][Full Text] [Related]
7. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
[TBL] [Abstract][Full Text] [Related]
8. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
[TBL] [Abstract][Full Text] [Related]
9. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
[TBL] [Abstract][Full Text] [Related]
10. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
11. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
[TBL] [Abstract][Full Text] [Related]
13. Alosetron and irritable bowel syndrome.
Mayer EA; Bradesi S
Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
[TBL] [Abstract][Full Text] [Related]
14. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
[TBL] [Abstract][Full Text] [Related]
15. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
Simrén M; Simms L; D'Souza D; Abrahamsson H; Björnsson ES
Aliment Pharmacol Ther; 2003 Jan; 17(2):279-87. PubMed ID: 12534414
[TBL] [Abstract][Full Text] [Related]
16. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
Humphrey PP; Bountra C; Clayton N; Kozlowski K
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
18. Alosetron in irritable bowel syndrome.
McColl KE
Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271
[No Abstract] [Full Text] [Related]
19. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
[TBL] [Abstract][Full Text] [Related]
20. Tegaserod and other serotonergic agents: what is the evidence?
Chey WD
Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
